Headline: PARP inhibition proves to be the first successful biomarker-driven systemic therapy for pancreatic cancer. The POLO trial enrolled 151 patients with germline BRCA-mutations and metastatic pancreatic cancer not progressing after at least 16 weeks of platinum chemo. They were then randomized to maintenance PARP inhibition with oral olaparib versus placebo. As predicted (with help), maintenance olaparib nearly doubled median progression-free survival from 3.8 → 7.4 months.
TBL: This won’t impact a terribly large amount of people, but it’s another clinical win for the theoretical effectiveness of PARP inhibition in the setting of BRCA-aberrations. | Golan, N Engl J Med 2019


Popular Posts